SCI Abstract

search
+
Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion
Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion
Cutaneous squamous cell carcinoma (CSCC) is the second most common skin malignancy in white-skinned populations. Only a mi...
Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines
Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines
Background:Evidence to date supports continued human epidermal growth factor receptor 2 (HER2) suppression beyond progress...
Predicting treatment outcomes using 18F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
Predicting treatment outcomes using 18F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
Background:Predictive markers for treatment response and survival outcome have not been identified in patients with advanc...
FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial
FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial
Background:FOLFIRI [irinotecan, folinic acid (CF), and fluorouracil] is considered a standard second-line chemotherapy reg...
PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study
PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study
Background:Perioperative chemotherapy is a recommended treatment approach for localised oesophago-gastric junction adenoca...
Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis
Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis
Background:Primary breast cancer (BC) has shown a higher immune infiltration than the metastatic disease, justifying the o...
Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy
Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy
Background:A reliable model is needed to estimate the risk of postoperative recurrence and the benefits of postoperative r...
Retraction notice: Downregulation of long noncoding RNA LINC01419 inhibits cell migration, invasion, and tumor growth and promotes autophagy via inactivation of the PI3K/Akt1/mTOR pathway in gastric cancer.
Retraction notice: Downregulation of long noncoding RNA LINC01419 inhibits cell migration, invasion, and tumor growth and promotes autophagy via inactivation of the PI3K/Akt1/mTOR pathway in gastric cancer.
Access to society journal content varies across our titles. If you have access to a journal via a society or association ...
Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)
Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)
Background:Standard intravenous (IV) paclitaxel is associated with hypersensitivity/toxicity. Alternative IV formulations ...
Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
Due to occupational asbestosis exposure, the incidence of malignant pleural mesothelioma (MPM) has continuously increased ...
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial
Purpose:To evaluate efficacy and safety of veliparib combined with carboplatin/paclitaxel in patients with advanced human ...
Can we develop oncolytic SARS-CoV-2 to specifically target cancer cells?
Can we develop oncolytic SARS-CoV-2 to specifically target cancer cells?
Access to society journal content varies across our titles. If you have access to a journal via a society or association ...
Correction notice to “Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model”
Correction notice to “Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model”
Chiao-Fang TengGraduate Institute of Biomedical Sciences, China Medical University, No.91, Hsueh-Shih Rd., Northern Dist....
Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)
Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)
Introduction:For epidermal growth factor receptor mutation-positive (EGFRm) non-small-cell lung cancer (NSCLC), EGFR-tyros...
A novel event-free survival endpoint in locally advanced pancreatic cancer
A novel event-free survival endpoint in locally advanced pancreatic cancer
The treatment paradigm for locally advanced pancreatic cancer (LAPC) is evolving rapidly. The development of neoadjuvant t...
Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects
Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects
Drug approval for early-stage breast cancer (EBC) has been historically granted in the context of registration trials base...
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
Background:The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cance...
Novel emerging biomarkers to immunotherapy in kidney cancer
Novel emerging biomarkers to immunotherapy in kidney cancer
The treatment of metastatic renal cell carcinoma has significantly evolved in recent years, particularly with the advent o...
Newly developed dual topoisomerase inhibitor P8-D6 is highly active in ovarian cancer
Newly developed dual topoisomerase inhibitor P8-D6 is highly active in ovarian cancer
Background:Ovarian cancer (OvCa) constitutes a rare and highly aggressive malignancy and is one of the most lethal of all ...
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
Background:Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is currently the standard second-li...
Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer
Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer
Purpose:This phase III study compared the efficacy and safety of proposed biosimilar MYL-1402O with reference bevacizumab ...
The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
Background:Adjuvant platinum-based chemotherapy is standard of care for patients with resected stage IIA/B or IIIA NSCLC. ...
Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial
Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial
Background:The aim of this study was to evaluate the efficacy and safety of gemcitabine plus nab-paclitaxel (GnP) as secon...
Comprehensive analysis of prognostic value of lymph node classifications in esophageal squamous cell carcinoma: a large real-world multicenter study
Comprehensive analysis of prognostic value of lymph node classifications in esophageal squamous cell carcinoma: a large real-world multicenter study
Background:We aim to assess the prognostic ability of three common lymph node–based staging algorithms, namely, the number...
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry
Background:Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Bre...
Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse model
Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse model
Background:Minibeam radiation therapy is an experimental radiation therapy utilizing an array of parallel submillimeter pl...
Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases
Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases
Background:The objective of this study was to construct a risk classification system integrating cell-free Epstein-Barr vi...
Ovarian metastases of pancreatic adenocarcinoma: clinical presentation, role of surgery, and potential value of the mutational profile for the differential diagnosis with primary mucinous ovarian carcinoma
Ovarian metastases of pancreatic adenocarcinoma: clinical presentation, role of surgery, and potential value of the mutational profile for the differential diagnosis with primary mucinous ovarian carcinoma
Background:Ovarian metastases (OM) of pancreatic adenocarcinoma (PA) (OM-PA) can mimic primary ovarian mucinous carcinoma ...
PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?
PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?
Prostate-specific membrane antigen (PSMA) is highly expressed on the membrane of most prostate cancer cells and to a lesse...
A case of advanced adenocarcinoma genetically confirmed with EGFR/BRAF co-mutation in both primary and metastatic lesions
A case of advanced adenocarcinoma genetically confirmed with EGFR/BRAF co-mutation in both primary and metastatic lesions
Driver mutations in lung cancer have been generally considered mutually exclusive; however, multiple gene screenings have ...
Load More
format_indent_increase